Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06244745
PHASE3

Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors.

Sponsor: IVI Madrid

View on ClinicalTrials.gov

Summary

The objective of this trial is to determine whether the use of letrozole during the luteal phase in oocyte donors diminishes the ovarian volume, as well as to evaluate its effect on the duration of the luteal phase, taking into account hormonal and biochemical markers. Two groups will be established with random allocation of patients and 1:1 proportionality, as follows: * Control group: No specific treatment. * Study group: Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.

Official title: Clinical and Endocrinological Effects of Letrozole During the Luteal Phase After Controlled Ovarian Stimulation in Oocyte Donors: a Low Interventional, Randomized, Controlled Trial

Key Details

Gender

FEMALE

Age Range

18 Years - 34 Years

Study Type

INTERVENTIONAL

Enrollment

152

Start Date

2023-12-15

Completion Date

2025-05-31

Last Updated

2025-05-21

Healthy Volunteers

Yes

Interventions

DRUG

Administration of letrozole

Oral administration of letrozole 5 mg (each capsule is 2.5 mg) once a day for 5 days starting on the night of the follicular puncture.

Locations (1)

IVI-Madrid

Madrid, Spain